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Abstract 
Background: Thrombospondin-1 (TSP-1) is an extracellular matrix protein that plays multiple 
physiological and pathophysiological roles in the brain. Experimental reports suggest that TSP-1 
may have an adverse role in neuronal function recovery under certain injury conditions. However, 
the roles of TSP-1 in traumatic brain injury (TBI) have not been elucidated. In this study we for the 
first time investigated the roles of TSP-1 in a controlled cortical impact (CCI) model of TBI in 
TSP-1 knockout (TSP-1 KO) and wild type (WT) mice. 
Methods: We examined blood brain-barrier (BBB) damage using at 1 day post-TBI by measuring 
Evans Blue leakage, and neurological functional recovery at 3 weeks post-TBI by measuring 
neurological severity score (NSS), wire gripping, corner test and Morris Water Maze (MWM). 
Mechanistically, we quantified pro-angiogenic biomarkers including cerebral vessel density, 
vascular endothelial growth factors (VEGF) and angiopoietin-1 (Ang-1) protein expression, 
synaptic biomarker synaptophysin, and synaptogenesis marker brain-derived neurotrophic factor 
(BDNF) protein expression in contralateral and ipsilateral (peri-lesion) cortex at 21 days after TBI 
using immunohistochemistry and Western Blot. 
Results: TSP-1 is upregulated at early phase of TBI in WT mice. Compared to WT mice, TSP-1 
KO (1) significantly worsened TBI-induced BBB leakage at 1 day after TBI; (2) had similar lesion size 
as WT mice at 3 weeks after TBI; (3) exhibited a significantly worse neurological deficits in motor 
and cognitive functions; (4) had no significant difference in cerebral vessel density, but significant 
increase of VEGF and Ang-1 protein expressions in peri-lesion cortex; (5) significantly increased 
BDNF but not synaptophysin protein level in peri-lesion cortex compared to sham, but both 
synaptophysin and BDNF expressions were significantly decreased in contralateral cortex 
compared to WT.  
Conclusion: Our results suggest that TSP-1 may be beneficial for maintaining BBB integrity in the 
early phase and functional recovery in late phase after TBI. The molecular mechanisms of TSP-1 in 
early BBB pathophysiology, and long-term neurological function recovery after TBI need to be 
further investigated. 
Key words: traumatic brain injury, Thromspondin-1 (TSP-1), neurological severity score (NSS), 
blood-brain-barrier, morris water maze (MWM), angiogenesis, synaptogenesis. 
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Introduction 
Thrombospondin-1 (TSP-1) is a member of 
the thrombospondin family, an extracellular matrix 
protein secreted mainly by astrocytes in the brain [1]. 
It has been known that TSP-1 mediates cell-cell and 
cell-matrix interactions through communicating with 
membrane receptors, other extracellular matrix 
proteins, and cytokines, thus playing important roles 
in multiple physiological processes including platelet 
function, vascular remodeling/angiogenesis, 
synaptogenesis, and wound healing [2, 3]. Multiple 
adhesion receptors for TSP-1 have been identified, 
including CD36, integrins, syndecan, and 
integrin-associated protein (IAP or CD47) [4]. Due to 
the multi-functions of TSP-1 in association with 
components of neurovascular unit, TSP-1 has been 
considered a new target for therapeutic development 
against traumatic brain injury [5-7]. However, the 
roles and mechanisms of TSP-1 in TBI remain 
unknown. Very importantly, a most recently 
published clinical study showed that TSP-1 was 
increased in plasma and highly associated with 
6-month mortality and unfavorable 6-month 
outcomes after traumatic brain injury, which further 
supports the rationale and significance for 
investigating the role of TSP-1 in TBI [8].  
We have previously found exposure to 4N1K, a 
specific CD47-activating peptide derived from TSP-1, 
induces neuronal cell death [9]. It also up-regulates 
vascular endothelial growth factor (VEGF) and matrix 
metalloproteinase-9 (MMP-9) in brain endothelial cell 
and astrocytes cultures, suggesting a potential role of 
TSP-1 in alteration of blood-brain barrier (BBB) 
homeostasis [10]. Moreover, besides regulating BBB 
integrity, emerging experimental reports have 
demonstrated that TSP-1 is mainly produced by 
astrocytes in the brain, which functions as an 
anti-angiogenic [11, 12], but pro- synaptogenesis 
factor [13].  
In the context of TBI pathophysiology, a complex 
cascade of processes is initiated following traumatic 
brain injury (TBI). Among them, three pathological 
events or mechanisms are closely linked to the TSP-1 
functions, including BBB integrity disruption at early 
acute injury phase, vascular 
remodeling/angiogenesis and synaptogenesis at late 
recovery phase, which in coordination control overall 
functional outcomes after TBI [14, 15]. Therefore, in 
this exploratory study, we investigated the roles of 
TSP-1 in neurological outcomes up to 3 weeks in a TBI 
model, performed with a controlled cortical impact 
device (CCI), in TSP-1 gene knockout (TSP-1 KO) and 
matching WT mice. Potential mechanisms involving 
BBB integrity disruption at early acute injury phase (1 
day), and vascular remodeling/angiogenesis and 
synaptogenesis at late recovery phase (3 weeks) are 
also examined.  
Materials and Methods 
Animals and CCI model 
Experimental protocols were approved by the 
Massachusetts General Hospital Animal Care and Use 
Committee in compliance with the National Institutes 
of Health Guide for the Care and Use of Laboratory 
Animals. 12-week-old mice of WT (C57BL/6J, Jackson 
Laboratory) and TSP-1 deletion (KO) 
(B6.129S2-Thbs1tmHyn/J, Jackson Laboratory) were 
used. Totally 142 mice (71 WT, 71 TSP 1-KO) were 
used in this study. TBI was conducted as previously 
reported [16, 17]. Briefly, the mice were anesthetized 
with 4% isoflurane and positioned in a stereotaxic 
frame. Anesthesia was maintained using 2–3% 
isoflurane. A midline longitudinal incision was then 
performed and the skin retracted and skull exposed. 
A 5.0 mm-diameter craniotomy was made in the left 
parietal bone midway between bregma and lambda 
with the medial edge 1 mm lateral to the midline. 
Mice were impacted at 5.0 m/s with a 40 ms dwell 
time and 0.6 mm depth using a 3 mm diameter convex 
tip, mimicking a moderate TBI based on literature [17, 
18]. The bone flap was discarded, and the scalp was 
sutured closed, surgical knots being used to secure the 
suture. The mice were then returned to their cages to 
recover from anesthesia. 
BBB leakage assessment 
The integrity of BBB was investigated by 
measuring the extravasation of evans blue at 24h after 
injury following our previously published protocol 
[19]. Briefly, evans blue dye (2% wt/vol in saline) in a 
volume of 4ml/kg was given by tail vein injection and 
allowed to circulate for 1 hour before being sacrificed. 
After cardio-perfusion with 0.1 mol/l 
phosphate-buffered saline, the mice were decapitated 
and brains were removed, weighed, and 
homogenized in 1.0 ml of trichloroacetic acid (50% in 
pure water), and centrifuged at 10,000 rpm for 20 min. 
Then 0.1 ml of the resultant supernatant was added to 
0.3 ml of ethanol (100%). The fluorescence were 
analyzed at 630nm for excitation and 680nm for 
emission using a spectrophotometer (SpectraMax M5, 
Molecular devices). The amount of Evans blue was 
quantified according to Evans blue external standard 
curve (25-2000 ng/ml) in 50% TCA /ethanol (1:3), and 
expressed as nanograms of Evans blue per gram of 
brain tissue.  
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Behavioral tests 
For the timeline of behavioral assay, previous 
studies have revealed that the injury effect for 
moderate CCI in mice generally lasts about 3-4 weeks, 
as summarized in a comprehensive review article by 
Fujimoto et al [20], and practiced by a large number of 
experimental studies [21-23], we therefore examined 
the behavioral deficit and brain lesion volume of the 
mice up to 21 days after CCI in this study. Before and 
after CCI (Day -1, 1, 3, 5, 7, 10, 14, 21), the behavioral 
function of the mice was evaluated according to a set 
of neurobehavioral tasks (neurological severity score, 
NSS), corner test and wire gripping test. A 10-point 
NSS was used for assessment of posttraumatic 
neurological impairment, as previous described [24, 
25]. The NSS was assessed at 1, 3, 5, 7, 10, 14 and 21 
days after TBI. All mice were trained and pre-tested 
prior to injury. Vestibulomotor function was assessed 
using a standard wire-grip test [26], and performed in 
triplicate and an average value calculated for each 
mouse on each day of testing. Furthermore, Morris 
Water Maze was applied to evaluate spatial memory 
performance after TBI as previously described [27]. 
Briefly, from 15 days post-CCI, five consecutive daily 
training sessions were performed to learn the 
locational quadrant of the slight underwater platform. 
For probe trial, the stay time and entry times into the 
platform area and target quadrant was recorded at 
day 21. To exclude the potential difference of visual 
ability between groups, extra visible trial was 
performed using a labeled platform above the surface 
of the water. The assessment process was carried out 
by an investigator who was blinded to the animal 
groups. 
Lesion volume 
Lesion volume was measured as we previously 
described [16]. Briefly, at day 21 after TBI, the animals 
were perfused with 0.1 mol/l phosphate-buffered 
saline under deep anesthesia. Brains were 
frozen-sectioned at the thickness of 10μm. Brain slices 
500μm apart were stained with hematoxylin and eosin 
(H&E) and photographed. The volume of injured 
tissue was measured with image J software. Damaged 
tissue volume = contralateral hemisphere volume- 
ipsilateral hemisphere volume. 
Immunohistochemistry 
Brain slices were air dried and fixed in 4% 
paraformaldehyde, then blocked in 5% fetal bovine 
serum for 80 minutes. After incubation overnight at 
4°C with rat anti-mouse CD31 (1:100, BD science), 
slides were analyzed using fluorescence microscope 
(ECLIPSE Ti-s, Nikon). For quantification of vessel 
density, the optical area fraction of CD31 positive cells 
per 20x field in the peri-lesion area was calculated in 4 
randomized areas (2 in cortex, and 2 in sub-cortex) in 
each animal.  
Western blot 
Western blot was performed following the 
protocols as we previously described [28]. Briefly, 
brain tissue dissected from contused cortex was 
homogenized in lysis buffer (cell signaling, 
Cambridge, MA) on ice, and centrifuged at 14,000 
RPM for 15mins at 4°C. Equal amount of protein were 
separated in a 4-20% Tris-glycine gel (Invitrogen) 
(40 μg/lane) and then transferred onto PVDF 
Membranes. Membranes were blocked for 1h in 5% 
non-Fat milk in Tris-buffered saline (pH 7.4) 
containing 0.1% Tween 20, then incubated overnight 
at 4°C with mouse anti-actin (Sigma Aldrich), mouse 
anti-synaptophysin (Millipore), rabbit anti-Ang-1 
(Abcam), rabbit anti-VEGF (Santa cruz) and rabbit 
anti-BDNF (Santa Cruz). After washing with PBST for 
three times, 20 min each, the membranes were then 
incubated for 1h with an appropriate horseradish 
peroxidase-conjugated secondary antibody at room 
temperature and developed by enhanced 
chemiluminescent (Pierce, Rockford, IL, USA). 
Densitometric analysis was performed for 
quantitation with Image J software. 
Statistical analysis 
Data are presented as Mean+SEM. Lesion 
volume, immunoblot and immunohistochemistry 
were analyzed by Student t test. Neurobehavioral 
assessments were analyzed by repeated measures 
ANOVA. Differences with P<0.05 were considered 
statistically significant.  
Results 
TSP-1 expression in peri-lesion cortex is 
transiently upregulated within 3 days after TBI 
TSP-1 gene deficiency was verified by 
genotyping with PCR using genomic DNA from 
TSP-1-KO mice. The size of PCR product from 
TSP-1-KO mice is as expected and clearly different 
from WT, confirming TSP-1 gene deficiency 
(supplemental Figure S1).  
To examine the expression of TSP-1 in response 
to TBI, we measured the TSP-1 protein level by 
Western blot at different time points following TBI. 
Three different antibodies for TSP-1 (mouse 
anti-TSP-1, NeoMarkers; mouse anti-TSP-1, Santa 
Cruz; rabbit anti-TSP-1, Abcam) were used to ensure 
the validity of Western blot. Our results showed that 
TSP-1 protein was not detectable in the mouse brain 
cortex before TBI. After TBI, TSP-1 expression in the 
peri-lesion cortex was significantly upregulated at 6 h 
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and lasted for 3 days, then returned to basal level 
(Figure 1A), showing a transient upregulation of 
TSP-1 expression during acute and sub-acute phases 
within about 3 days after TBI. 
TSP-1 knockout worsens CCI-induced BBB 
permeability increase 
To test the effect of TSP-1 knockout on BBB 
permeability after CCI, we examined Evans blue 
extravasation into the brain at 24h after TBI 
(n=4/group). We noticed there was a very low level of 
Evans blue extravasation in contralateral hemisphere, 
no difference between TSP-1 KO and WT mice, 
indicating a similar baseline of BBB permeability at 
least to large molecules in both group mice. As 
expected, TBI significantly increased Evans blue 
extravasation in ipsilateral hemisphere of both TSP-1 
KO and WT mice, however, this increase of Evans 
blue extravasation was significantly potentiated in 
TSP-1 KO mice compared to WT mice, (Figure 1B), 
demonstrating that TSP-1 gene knockout exacerbates 
TBI-induced BBB permeability. 
 
 
Figure 1. Effects of TSP-1 knockout on BBB leakage and brain lesion in mice after TBI. To examine the contribution of TSP-1 in the outcomes of TBI, we 
first measured the TSP-1 protein expression changes in response to TBI, then measured the BBB leakage and brain lesion volumes in TSP-1 KO mice and WT mice. 
(A) Representative Western Blot image of TSP-1 protein levels in the ipsilateral hemisphere at 6 h, 1d, 3d, 5d, 7d, 10d, 14d, 21d following TBI. Samples from TSP-1 
KO mice was used as negative control (n=4 for each time point). (B) BBB leakage was measured and quantified at 24 hrs after TBI by testing Evans Blue extravasation 
(n=4, *p<0.05 vs WT group). (C) Brain lesion volume was measured and quantified at 28 days after TBI (n=16). 
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TSP-1 knockout does not alter brain lesion 
volumes after TBI 
To examine if TSP-1 contributes to the brain 
tissue damage progression after TBI, we assessed 
brain lesion volumes of WT and TSP-1 KO mice at 28 
days post-TBI (n=16/group). Our results show that 
there were no significant differences in lesion volumes 
between WT and TSP-1 KO mice after CCI (Figure 
1C), suggesting that TSP-1 gene knockout during the 
first 3 weeks does not affect brain tissue damage 
progression.  
TSP-1 knockout potentiates neurological 
function deficits after TBI 
To determine the roles of TSP-1 in neurological 
functional recovery after TBI, we assessed and 
compared the motor-sensor behavior outcomes, 
including neurological severity score (NSS), wire grip 
and corner test, in WT and TSP-1 KO mice at 1 day 
before TBI (day -1) and day 1, 3, 5, 7, 10, 14, 21 after 
TBI (n=16/group). As expected, the motor-sensor 
functions were significantly impaired by TBI. For 
NSS, TSP-1 KO mice had significantly worse recovery 
compared to WT mice (Figure 2A). While both wire 
grip and corner test of WT and TSP-1 KO mice 
recovered to baseline at 10 days post-TBI, no 
significant differences were detected between the two 
groups (Figure 2B, 2C). These data indicate a 
significantly worsened motor-sensor function 
recovery by the gene knockout of TSP-1 after TBI.  
 
 
Figure 2. Effect of TSP-1 knockout on behavior outcomes in mice after TBI. Neurological function outcomes were measured after TBI in TSP-1 KO and 
WT mice. Motor-sensor functions including NSS, wire gripping and corner test were assessed before and 1d, 3d, 5d, 7d, 10d, 14d, 21d after TBI. (A) NSS test; (B) wire 
gripping test; (C) corner test. Moreover, spatial memory ability was assessed by Morris Water Maze starting from 14d post-TBI. (D) latency training; (E) probe trials 
measuring the entry times to platform; (F) probe trials measuring the stay time in targeted quadrant. (n=16, * p<0.05 vs WT group).  
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To examine the effect of TSP-1 knockout on 
post-injury cognitive function, we performed Morris 
water maze (MWM) assay starting from 14 days after 
TBI for 5 consecutive days. Both WT and TSP-1 KO 
groups showed a time-dependent improvement in 
latency to hidden platform tests. WT group showed 
significantly better improvement than TSP-1 KO 
group in latency to find the hidden platform (Figure 
2D), but no differences were detected in probe tests 
between the two groups measuring entry times or 
time stay in platform and target quadrant (Figure 2E, 
2F), suggesting that TSP-1 knockout might potentiate 
the TBI-induced memory loss.  
TSP-1 knockout does not change vessel 
density, but elevates pro-angiogenic factors 
VEGF and Ang-1 expression after TBI 
To investigate whether TSP-1 knockout affects 
vascular remodeling/angiogenesis after TBI, we 
tested brain vessel density in WT and TSP-1 KO mice 
by immunostaining with anti-CD31 antibody at 21 
days post-TBI (n=4/group). In the sham control 
cortex, there was no significant difference between 
TSP-1 KO and WT mice. TBI did not increase the 
vessel density in contralateral peri-lesion cortex of 
both groups. However, TBI significantly increased the 
vessel density in ipsilateral peri-lesion cortex, but no 
difference was detected between the WT and TSP-1 
KO groups (Figure. 3A, 3B). These data suggest that 
TSP-1 knockout may not alter brain vessel density 
during development and after TBI. 
 
 
Figure 3. Effect of TSP-1 knockout on vessel density and vascular response in mouse brains after CCI. At 21 days after TBI, the brain vessel density in 
the peri-lesion cortex area was measured by immunostaining with anti-CD31 antibody. Vascular responses was measured by testing the protein expression of 
angiogenic factors VEGF and Ang-1. (A) Representative images of CD31-positive vessels in the ipsilateral peri-lesion cortex at 21 days after TBI or sham operation 
(Scale bar =50um). (B) Quantitative analysis of vessel density defined as the area fraction of positive signal. (n=4/group). (C) Representative images of Western blot 
for VEGF and Ang-1 protein levels in sham and injured hemispheres at 21 days after TBI (n=4/group). (D) Quantification of VEGF protein level showed no difference 
between WT and TSP-1 KO groups. (E) Quantification of Ang-1 protein level showed significant increase in the ipsilateral hemisphere of TSP-1 KO mice compared 
with WT mice, after TBI (n=4/group). (# p<0.05 vs sham, *p<0.05 vs WT group).  
Int. J. Med. Sci. 2017, Vol. 14 
 
 
http://www.medsci.org 
933 
To delineate the vascular signaling response to 
brain trauma, we measured the typical 
pro-angiogenic factors VEGF and Ang-1 expression at 
21 days after TBI (n=4/group). No significant 
differences were detected in sham level of VEGF and 
Ang-1 between WT and TSP-1 KO mice. There was 
slight decrease (but no significance) of VEGF and 
Ang-1 protein expression in contralateral peri-lesion 
cortex compared to the sham controls and between 
WT and TSP-1 KO mice after TBI. However, the 
expression of both VEGF and Ang-1 were 
significantly increased in the ipsilateral peri-lesion 
cortex of TSP-1 KO mice after TBI compared with 
sham, or WT control group (Figure. 3C, 3D, 3E). These 
data indicate that Tsp-1 gene knockout significantly 
elevated the two pro-angiogenic factors VEGF and 
Ang-1 protein expression, but might not significantly 
alter vascular histological response, at least in vessel 
density.  
TSP-1 Knockout diminishes synaptogenic 
responses in contralateral but not ipsilateral 
cortex after TBI 
To determine the effect of TSP-1 knockout on 
synaptogenic response following TBI, a biomarker for 
synapse quantification [29], synaptophysin, was 
examined in the brain cortex by Western blot at 21 
days after TBI (n=4/group). In shame control animals, 
we detected a similar baseline level of synaptophysin 
expression in cerebral cortex of both WT and TSP-1 
knockout mice (Figure 4A, 4B), suggesting the 
quantity of synapse is not altered by TSP-1 gene 
depletion at pre-TBI baseline. After TBI, we found a 
slight and similar increase (~20%) of synaptophysin 
expression in both contralateral and ipsilateral cortex 
of WT mice, and ipsilateral cortex of TSP-1 KO mice, 
compared to the sham controls. Interestingly, there 
was a significant decrease of synaptophysin 
expression in the contralateral hemisphere cortex of 
TSP-1 KO mice compared to its sham (~20% 
decrease), contralateral cortex of WT (~33% decrease) 
and ipsilateral (~30% decrease) hemisphere cortex 
(Figure 4A, 4B) of TSP-1 KO mice, indicating TSP-1 
gene depletion diminishes synaptogenic response of 
contralateral cortex after TBI. However, the similar 
synaptophysin level in the ipsilateral cortex of the two 
groups indicates a different response in the injured 
cortex that may compensate for TSP-1 
deficiency-associated synaptophysin decrease in the 
contralateral cortex after TBI.  
Since BDNF is an important neurotrophic factor 
that promotes both vascular remodeling and synaptic 
plasticity during recovery phase after TBI [30], we 
therefore examined BDNF protein expression at 21 
days after TBI (n=4/group). We found there was no 
significant difference of BDNF protein expression at 
cortex between WT and TSP-1 KO mice (Figure 4A, 
4C). TBI significantly increased BDNF expression in 
ipsilateral cortex of both WT (~70% increase) and 
TSP-1 KO (~105% increase) mice compared to the 
sham controls, but there was no significance 
difference between the two groups. However, in the 
contralateral cortex, BDNF expression was not altered 
by TBI in TSP-1 KO mice; in contrast, TBI significantly 
increased BDNF expression in the contralateral cortex 
compared to its sham control (~60% increase), and 
TSP-1 KO mice (~45% increase) (Figure 4A, 4C). These 
data indicate that similarly as synaptophysin, there is 
a different response in the injured cortex that may 
compensate the TSP-1 gene depletion-associated 
resistance of BDNF expression in the contralateral 
cortex after TBI.  
 
 
Figure 4. Effect of TSP-1 knockout on synaptogenic responses in 
mouse brains after TBI. Synaptogenic response was examined by testing 
synaptophysin and BDNF protein levels in bilateral hemispheres by Western 
blot at 21 days after TBI. (A) Representative Western blot images for 
synaptophysin and BDNF in sham and injured brain tissue (n=4/group). (B) 
Quantification of synaptophysin protein levels showed significant decrease in 
the contralateral hemisphere of TSP-1 KO mice after TBI, compared with WT. 
(C) Quantification of BDNF protein level showed significant decrease in the 
contralateral hemisphere of TSP-1 KO mice compared to WT after TBI, and 
significant elevation in the ipsilateral hemisphere of both groups compared to 
sham after TBI. (# p<0.05 vs sham, *p<0.05 vs WT group). 
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Discussion 
Compared to WT control mice, our experimental 
results showed that TSP-1 KO (1) significantly 
worsened TBI-induced BBB leakage at 1 day after TBI; 
(2) had similar lesion size as WT mice at 3 weeks after 
TBI; (3) exhibited a significantly worse neurological 
deficits in motor function, and cognitive function; (4) 
had no significant difference in cerebral vessel 
density, but a significant increase of VEGF and Ang-1 
protein expression in peri-lesion cortex; (5) 
significantly increased BDNF but not synaptophysin 
protein level in peri-lesion cortex compared to sham, 
but both synaptophysion and BDNF expressions were 
significantly decreased in contralateral cortex 
compared to WT.  
In this study we found TSP-1 KO mice exhibited 
significantly worse motor sensory function deficit and 
significantly more impairment in learning ability 
compared to WT controls at 3 weeks after TBI (Figure 
2). However, no difference in lesion size was detected 
between the two groups (Figure 1). The roles of TSP-1 
in BBB permeability in the acute phase after brain 
injury have not been fully examined in vivo. Only 
limited knowledge was learnt from in vitro 
endothelial cell culture studies, but the results were 
controversial. One study suggested that increased 
TSP-1 expression was associated with the roles of 
astrocytes under reoxygenation acting as a significant 
driving force for BBB maturation [31], but many other 
studies imply that TSP-1 is a destabilizing factor of 
endothelial barrier [32, 33]. In this study we for the 
first time show that TSP-1 KO potentiated 
TBI-mediated BBB permeability disruption. We did 
not find any increase of Evans blue BBB leakage in the 
contralateral hemisphere of TSP-1 KO mice, 
indicating TSP-1 KO might not alter physiological 
resting baseline of BBB permeability, at least to larger 
size molecules. Although earlier in vitro experimental 
reports have suggested TSP-1 is an inflammatory 
mediator which can cause endothelial cell death and 
permeability increase via activating TGFβ, binding 
CD47 and upregulating MMP-9 [34, 35], our results 
for the first time reveals that TSP-1 may play an 
important role in maintaining, but not disrupting, 
BBB integrity after brain injury. Moreover, it raises an 
important notion that more preclinical investigations 
are needed to define the roles of TSP-1 in brain 
injury-induced BBB damage and associated 
pathophysiology. 
Among many physiological functions of TSP-1, 
anti-angiogenesis and pro-synaptogenesis are two 
major functions closely related to post TBI functional 
recovery process [36, 37]. After TBI, angiogenesis may 
provide the critical neurovascular microenvironment 
for neuronal remodeling [38]. Two mechanistic 
biomarkers, VEGF and Ang-1, which can promote 
angiogenesis and vascular stability after TBI [39], 
were examined and compared in this study. 
Synaptogenesis forms new connections between 
existing neurons [40]; synaptophysin is a commonly 
used biomarker [29]. Additionally, BDNF was also 
selected as a biomarker for synaptogenesis in this 
study, since BDNF can cause neural regeneration, 
reconnection, and dendritic sprouting, and can 
improve synaptic efficacy [30]. 
In this study we observed transient upregulation 
of TSP-1 protein expression within 3 days after TBI, 
suggesting that TSP-1 actively responds to TBI, and 
might play a more important role at acute and 
sub-acute phases. A previous study also detected a 
peak elevation of TSP-1 expression in the first three 
days after focal cerebral ischemia of rats, however, 
TSP-2 was elevated peaking at two weeks after 
ischemia [41]. Both TSP-1 and TSP-2 are mostly 
produced by astrocytes, belonging to a family of 
extracellular glycoproteins with very similar 
angiostatic and synaptogenic properties [12, 13]. Very 
interestingly, a previous study reported that TSP-1/2 
double KO mice exhibited significantly impaired 
motor function recovery after stroke. The TSP-1/2 
double KO mice had significant deficits in synapse 
density and axonal sprouting, but had not difference 
in brain vessel density compared to WT control [42].  
In the present study, at late three weeks after 
TBI, there were no differences between the two group 
mice on VEGF-A and Ang-1 expressions in 
contralateral hemisphere, but both were significantly 
increased in ipsilateral hemisphere of TSP-1 KO mice, 
suggesting vascular remodeling response may be 
potentiated from the TSP-1 KO mice after TBI. 
However we found brain vessel density was 
significantly increased after TBI, but no difference 
between the two group mice (Figure 3), which might 
be speculated that possible involvements of other 
anti- or pro- vascular remodeling factors in the late 
vascular response. Furthermore, we found a 
significant decline of synaptogenesis markers 
synaptophysin and BDNF expression in the 
contralateral cortex, but not in the sham and 
ipsilateral cortex of TSP-1 KO mice compared to the 
WT controls. We speculate that TSP-1 depletion might 
lead to a latent response for synaptogenesis in the 
contralateral hemisphere at late phase after TBI, while 
other signaling molecules such as TSP-2 in the injured 
hemisphere might actively respond to TBI and 
compensate the latency caused by the TSP-1 
deficiency [42]. 
There are a few caveats in this study. Firstly, 
although previous studies suggest that astrocytes is 
the major source of TSP-1 in the brain [43], due to the 
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lack of reliable anti-TSP-1 antibodies for 
immunohistochemistry, we were unable to dissect 
cellular localization of TSP-1 protein expression in this 
study, further investigations on the cellular sources of 
TSP-1 will be conducted in the future. Secondly, 
vascular remodeling and synaptogenesis may take 
several months after TBI, but we only examined one 
single time point, i.e, 21 days after CCI. Examination 
for these important endogenous recovery 
mechanisms for longer time at multiple time points 
would facilitate better understanding of the roles and 
mechanisms of TSP-1. Third, in this study we 
observed worsened neurological outcome in TSP-1 
KO mice, associated with decreased synaptophysin 
and BDNF expressions, but increased 
pro-angiogenesis markers VEGF and Ang-1. 
However, the causality between these phenomena has 
not been established, which warrants further 
investigation in the future. Lastly, the different 
responses of TSP-1 KO to TBI versus WT mice might 
be partially due to TSP-1 gene deficiency-associated 
developmental deficits that result in alterations in key 
signaling pathways of pre-TBI baseline. The baseline 
changes of molecular signaling needs to be carefully 
characterized for better result interpretation. TSP-1 
conditional and inducible gene KO mice would 
therefore be more powerful tools for further 
evaluating the roles and mechanisms of TSP-1 in TBI.  
In summary, in this study we found TSP-1 
protein expression was transiently up-regulated 
within the first 3 days after TBI. TSP-1 may be 
beneficial for maintaining BBB integrity in the early 
phase, but its role for functional recovery in the late 
phase of TBI remains unclear. The pathological roles 
and molecular mechanisms of TSP-1 in early BBB 
pathophysiology, and long-term neurological 
function recovery after TBI need to be further 
investigated. 
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